
PMN Stock Forecast & Price Target
PMN Analyst Ratings
Bulls say
ProMIS Neurosciences Inc demonstrates a promising outlook as favorable biomarker and safety data related to its lead candidate, PMN310, indicate a mechanistic advantage that bolsters rationale for continued investment ahead of forthcoming 12-month results. Additionally, the strong selectivity profile of PMN267, which is advancing toward clinical development, suggests potential for effective disease-modifying activity and an enhanced safety margin across various neurodegenerative diseases, including ALS and frontotemporal dementia. Collectively, these factors highlight the company's strategic positioning within the biotechnology sector, underpinned by its innovative methodologies for targeting toxic misfolded proteins.
Bears say
ProMIS Neurosciences faces a negative outlook due to several fundamental issues highlighted in the recent financial excerpts. There is a concern regarding the effectiveness of its lead treatment, PMN310, despite showing some promise in restoring learning and spatial memory in animal models, as the overall success of therapies targeting neurodegenerative diseases has been historically limited by complex mechanistic understandings and poor correlation with clinical outcomes. Additionally, the potential for partnership risks, slower-than-anticipated market uptake due to competition, and the looming threat of dilution further complicate the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
PMN Analyst Forecast & Price Prediction
Start investing in PMN
Order type
Buy in
Order amount
Est. shares
0 shares